 |
市場調查報告書
商品編碼
1572486
抽動穢語症候群治療市場、機會、成長動力、產業趨勢分析與預測，2024-2032Tourette Syndrome Treatment Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032 |
||||||
2023年，全球抽動穢語症候群治療市場價值為24億美元，預計2024年至2032年複合年成長率為4.8%。推動的。美國疾病管制與預防中心 (CDC) 的數據顯示，美國 5 至 17 歲的兒童中，大約每 160 名就有 1 名被診斷患有抽動穢語綜合症，這凸顯了對有效治療的需求。治療方法的突破，包括行為復健和創新藥理解決方案，拓寬了抽動穢語症候群的治療前景。基因研究和神經影像學的進步加深了對此病機制的了解，從而製定了更有針對性的治療策略。
整個抽動穢語綜合症治療行業根據治療類型、疾病類型、年齡層、最終用途和地區進行分類。
到 2023 年，藥物領域以 15 億美元佔據市場主導地位。主要治療方法包括 FDA 核准的抗精神病藥物，如阿立哌唑和利培酮，以及標籤外 α-腎上腺素激動劑，如可樂定和胍法辛。個人化醫療的進步和針對特定神經傳導物質途徑的新治療藥物的開發為更有效、減少副作用的治療提供了有希望的機會。
市場根據疾病類型將治療方法分為發聲抽動症和運動抽動症。 2023 年，運動抽動症佔了 63.5% 的主導市場。眨眼、搖頭或聳肩等運動抽動是治療介入的核心，並在治療市場中佔有相當大的佔有率。運動抽搐的廣泛發生及其對日常生活的影響凸顯了其市場主導地位，導致了一系列旨在減輕症狀和提高生活品質的專門治療。
到 2032 年，北美抽動穢語症候群治療市場預計將達到 15 億美元，複合年成長率為 5%。由於其先進的醫療基礎設施和持續的神經系統疾病研究，美國在北美市場中發揮著舉足輕重的作用。意識的提高、更好的診斷方法和治療方案的進步正在推動美國市場的發展。隨著對有效治療的需求增加，美國有望繼續成為北美市場的主導力量。
目錄
第 1 章：方法與範圍
第 2 章：執行摘要
第 3 章：產業洞察
- 產業生態系統分析
- 產業影響力
- 成長動力
- 神經系統疾病盛行率不斷上升
- 藥物開發的進展
- 產業陷阱與挑戰
- 先進療法的高成本
- 副作用和不良反應
- 成長動力
- 成長潛力分析
- 監管環境
- 未來市場趨勢
- 波特的分析
- PESTEL分析
第 4 章：競爭格局
- 介紹
- 公司矩陣分析
- 主要市場參與者的競爭分析
- 競爭定位矩陣
- 戰略儀表板
第 5 章：市場估計與預測：按治療類型，2021 - 2032 年
- 主要趨勢
- 藥物
- α-腎上腺素激動劑
- 抗精神病藥
- 興奮劑
- 肉毒毒素注射
- 其他藥物類型
- 行為療法
- 抽動症綜合行為介入（CBIT）
- 習慣逆轉訓練
- 深部腦部刺激（DBS）
- 其他治療類型
第 6 章：市場估計與預測：按疾病類型，2021 - 2032
- 主要趨勢
- 運動抽搐
- 聲音抽搐
第 7 章：市場估計與預測：按年齡分類，2021 - 2032
- 主要趨勢
- 兒科
- 成人
第 8 章：市場估計與預測：按最終用途，2021 - 2032 年
- 主要趨勢
- 醫院
- 專科診所
- 家庭護理設置
- 其他最終用戶
第 9 章：市場估計與預測：按地區，2021 - 2032
- 主要趨勢
- 北美洲
- 美國
- 加拿大
- 歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
- 亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地區
- 中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區
第 10 章：公司簡介
- Service Provider
- Medication Manufacturer
The Global Tourette Syndrome Treatment Market was valued at USD 2.4 billion in 2023 and is projected to grow at a CAGR of 4.8% from 2024 to 2032. The market's growth is driven by the rising incidence of Tourette syndrome, enhanced diagnostic capabilities, and increased awareness. Data from the CDC indicates that roughly 1 in 160 children aged 5 to 17 in the U.S. is diagnosed with Tourette syndrome, highlighting the demand for effective treatments. Breakthroughs in therapeutic methods, including behavioral rehabilitation and innovative pharmacological solutions, have broadened the management landscape for Tourette syndrome. Advancements in genetic research and neuroimaging have deepened the understanding of the condition's mechanisms, leading to more tailored treatment strategies.
The overall tourette syndrome treatment industry is classified based on the treatment type, disease type, age group, end-use and region.
The medication segment dominated the market with USD 1.5 billion in 2023. The medication segment is essential for alleviating the symptoms of Tourette syndrome, focusing on motor and vocal tics that interfere with daily life. Key treatments include FDA-approved antipsychotics such as aripiprazole and risperidone, as well as off-label alpha-adrenergic agonists like clonidine and guanfacine. Advances in personalized medicine and the creation of new therapeutic agents targeting specific neurotransmitter pathways present promising opportunities for more effective treatments with reduced side effects.
The market categorizes treatments based on disease type into vocal tics and motor tics. In 2023, motor tics commanded a dominant market share of 63.5%. Motor tics, such as blinking, head jerking, or shoulder shrugging, are central to therapeutic interventions and hold a substantial share in the treatment market. The widespread occurrence and daily life impact of motor tics underscore their market dominance, leading to a range of specialized treatments aimed at alleviating symptoms and enhancing quality of life.
By 2032, the North American Tourette syndrome treatment market is projected to reach USD 1.5 billion, growing at a CAGR of 5%. The U.S. plays a pivotal role in North America's market due to its advanced healthcare infrastructure and ongoing neurological disorder research. Heightened awareness, better diagnostic methods, and advancements in treatment options are driving the market in the U.S.Strong advocacy from organizations like the Tourette Association of America enhances public understanding and support for those with Tourette syndrome. The U.S. is poised to remain a dominant force in North America's market as the demand for effective treatments rises.
Table of Contents
Chapter 1 Methodology and Scope
- 1.1 Market scope and definitions
- 1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
- 1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources
Chapter 2 Executive Summary
- 2.1 Industry 360° synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Growing prevalence of neurological disorders
- 3.2.1.2 Advancements in drug development
- 3.2.2 Industry pitfalls and challenges
- 3.2.2.1 High cost of advanced therapies
- 3.2.2.2 Side effects and adverse reactions
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
- 3.5 Future market trends
- 3.6 Porter's analysis
- 3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
- 4.1 Introduction
- 4.2 Company matrix analysis
- 4.3 Competitive analysis of major market players
- 4.4 Competitive positioning matrix
- 4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Treatment Type, 2021 - 2032 ($ Mn)
- 5.1 Key trends
- 5.2 Medication
- 5.2.1 Alpha-adrenergic agonists
- 5.2.2 Antipsychotics
- 5.2.3 Stimulants
- 5.2.4 Botulinum toxin injection
- 5.2.5 Other medication types
- 5.3 Behavioral therapy
- 5.3.1 Comprehensive Behavioral Intervention for Tics (CBIT)
- 5.3.2 Habit reversal training
- 5.4 Deep brain stimulation (DBS)
- 5.5 Other treatment types
Chapter 6 Market Estimates and Forecast, By Disease Type, 2021 - 2032 ($ Mn)
- 6.1 Key trends
- 6.2 Motor tics
- 6.3 Vocal tics
Chapter 7 Market Estimates and Forecast, By Age Group, 2021 - 2032 ($ Mn)
- 7.1 Key trends
- 7.2 Pediatric
- 7.3 Adult
Chapter 8 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)
- 8.1 Key trends
- 8.2 Hospitals
- 8.3 Specialty clinics
- 8.4 Homecare settings
- 8.5 Other end-users
Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)
- 9.1 Key trends
- 9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
- 9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.3.7 Rest of Europe
- 9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
- 9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.5.4 Rest of Latin America
- 9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
- 10.1 Service Provider
- 10.1.1 Boston Children's Hospital
- 10.1.2 Mayo Clinic
- 10.1.3 Stony Brook Medicine
- 10.1.4 Massachusetts General Hospital
- 10.1.5 UPMC Children's Hospital of Pittsburgh
- 10.2 Medication Manufacturer
- 10.2.1 AstraZeneca PLC
- 10.2.2 Bausch Health Companies Inc.
- 10.2.3 Catalyst Pharmaceuticals, Inc.
- 10.2.4 Eli Lilly and Company
- 10.2.5 Emalex Biosciences, Inc.
- 10.2.6 Novartis AG
- 10.2.7 Otsuka Pharmaceutical Co., Ltd.
- 10.2.8 Sun Pharmaceutical Industries Limited
- 10.2.9 Teva Pharmaceutical Industries Limited
